Abstract: The present disclosure is directed to methods and/or uses of oligonucleotide conjugates for assays and flow cytometry detections and related systems and/or kits. Certain methods are directed to a method for detecting one or more biological targets of a sample in a detection assay, comprising: providing a molecular probe, comprising a binding moiety and an oligonucleotide sequence, to a sample comprising one or more biological targets; binding the one or more biological targets with the binding moiety; providing a detectable component to the sample, wherein the detectable component comprises a signal generating moiety conjugated to an oligonucleotide sequence complementary to the oligonucleotide sequence of the molecular probe; hydridizing the oligonucleotide sequence of the target-bound molecular probe to the detectable component; and detecting a signal generated from the hydridized detectable component. Various other embodiments, applications etc. are disclosed herein.

Abstract: Provided are wound sealer components, comprising: an upper surface, a bottom surface, a vacuum chamber defined between the upper surface and the lower surface, the bottom surface defining at least one vacuum chamber opening in fluid communication with the vacuum chamber, and the vacuum chamber opening being defined between vacuum chamber opening edges of the component; a vacuum tap that places the vacuum chamber into fluid communication with the environment exterior to the vacuum tap, the vacuum tap being adapted for application of vacuum within the vacuum chamber, the at least one vacuum chamber opening being adapted to, upon application of sufficient vacuum from the tap, securably engage with tissue proximate to the bottom surface by drawing at least some of the tissue toward or even into the vacuum chamber so as to stably affix the component to the tissue, and a sealer portion, the sealer portion configured such that application of vacuum to draw tissue toward or even into the vacuum chamber exerts the sea

Abstract: The instant disclosure provides reagent compounds, and antibody and oligonucleotide reagents, for use in a variety of assays, including immunoassays and nucleic acid hybridizations. The reagent compounds comprise a bridging antigen or bridging oligonucleotide and a latent crosslinker moiety, such as a tyramide moiety. The bridging antigens are recognizable by the antibody of a corresponding antibody reagent with high affinity, and the bridging oligonucleotides are complementary to the oligonucleotide of a corresponding oligonucleotide reagent. The antibody reagents and oligonucleotide reagents also comprise a crosslinker activation agent, such as a peroxidase enzyme. Reaction of the reagent compounds with the crosslinker activation agent results in the amplification of signal in assays for target cellular markers, including cellular antigens and nucleic acids.

Abstract: Disclosed herein are agents that target telomerase reverse transcriptase (TERT) for treating cancer and sensitizing cancer cells to genotoxic therapy. The methods include inhibiting induction of an immunosuppressive factor in a subject in need thereof, the method comprising administering an inhibitor of TERT to the subject.

Abstract: The instant disclosure provides reagent compounds, and antibody and oligonucleotide reagents, for use in a variety of assays, including immunoassays and nucleic acid hybridizations. The reagent compounds comprise a bridging antigen or bridging oligonucleotide and a latent crosslinker moiety, such as a tyramide moiety. The bridging antigens are recognizable by the antibody of a corresponding antibody reagent with high affinity, and the bridging oligonucleotides are complementary to the oligonucleotide of a corresponding oligonucleotide reagent. The antibody reagents and oligonucleotide reagents also comprise a crosslinker activation agent, such as a peroxidase enzyme. Reaction of the reagent compounds with the crosslinker activation agent results in the amplification of signal in assays for target cellular markers, including cellular antigens and nucleic acids.

Abstract: Using whole blood viscosity (WBV) data collected at various shear rates in conjunction with other clinically relevant information—such as age, gender, and other medical history information—one can generate information indicative of a current or physiological condition of a subject. Such generation can be accomplished using machine learning, such as a trained algorithm. One can also train an algorithm using WBV and other clinically relevant information. The described approaches allow for early detection and treatment of conditions, such as sepsis, as well as the evaluation of a treatment or treatments administered to a patient in need.

Abstract: Provided are apparatuses and methods for rapid viscometry of whole blood, plasma, and/or whole blood during coagulation. The disclosed technology measures the blood viscosity through the full range of flow rates found in the cardio-vascular system. This in vitro test can be performed on fresh or anticoagulated whole blood to predict the flow properties (e.g., viscosity) anywhere in the body from the aorta to the deep veins of the leg. The result is a flow-rate dependent blood viscosity curve (viscosity profile) that helps the clinician predict and manage the patient's vulnerability to thrombosis and embolism, which is of particular relevance to COVID-19 patients and/or ICU patients.

Abstract: Provided are apparatuses and methods for rapid viscometry of whole blood, plasma, and/or whole blood during coagulation. The disclosed technology measures the blood viscosity through the full range of flow rates found in the cardio-vascular system. This in vitro test can be performed on fresh or anticoagulated whole blood to predict the flow properties (e.g., viscosity) anywhere in the body from the aorta to the deep veins of the leg. The result is a flow-rate dependent blood viscosity curve (viscosity profile) that helps the clinician predict and manage the patient's vulnerability to thrombosis and embolism, which is of particular relevance to COVID-19 patients and/or ICU patients.

Abstract: The present disclosure is directed to methods and/or uses of oligonucleotide conjugates for assays and flow cytometry detections and related systems and/or kits. Certain methods are directed to a method for detecting one or more biological targets of a sample in a detection assay, comprising: providing a molecular probe, comprising a binding moiety and an oligonucleotide sequence, to a sample comprising one or more biological targets; binding the one or more biological targets with the binding moiety; providing a detectable component to the sample, wherein the detectable component comprises a signal generating moiety conjugated to an oligonucleotide sequence complementary to the oligonucleotide sequence of the molecular probe; hydridizing the oligonucleotide sequence of the target-bound molecular probe to the detectable component; and detecting a signal generated from the hydridized detectable component. Various other embodiments, applications etc. are disclosed herein.

Abstract: Provided are devices and methods suitable for immobilizing tissue and for use in non-invasive methods of assessing lower urinary tract symptoms as well as in surgical application.

Abstract: The instant disclosure provides reagent compounds, and antibody and oligonucleotide reagents, for use in a variety of assays, including immunoassays and nucleic acid hybridizations. The reagent compounds comprise a bridging antigen or bridging oligonucleotide and a latent crosslinker moiety, such as a tyramide moiety. The bridging antigens are recognizable by the antibody of a corresponding antibody reagent with high affinity, and the bridging oligonucleotides are complementary to the oligonucleotide of a corresponding oligonucleotide reagent. The antibody reagents and oligonucleotide reagents also comprise a crosslinker activation agent, such as a peroxidase enzyme. Reaction of the reagent compounds with the crosslinker activation agent results in the amplification of signal in assays for target cellular markers, including cellular antigens and nucleic acids.

Abstract: The present disclosure is directed to high-affinity immunopolymers for use in a variety of immunoassays and other techniques. The immunopolymers comprise a plurality of antibodies, a plurality of coupling proteins, and a plurality of detectable labels. The plurality of antibodies and plurality of coupling proteins are associated by a high-efficiency conjugation moiety, and may be used in highly multiplexed assays. Methods of preparing the high-affinity immunopolymers are provided. Also disclosed are methods of detecting an antigen that include reacting an antigen with a high-affinity immunopolymer of the disclosure. Reagent mixtures and methods for quantitative immunochemical assays are also provided. The mixtures and methods may include the high-affinity immunopolymers disclosed herein.

Abstract: Provided are devices and methods suitable for immobilizing tissue and for use in non-invasive methods of assessing lower urinary tract symptoms as well as in surgical application.

Abstract: Provided are devices and methods suitable for immobilizing tissue and for use in non-invasive methods of assessing lower urinary tract symptoms as well as in surgical application.

Abstract: Provided are devices and methods suitable for immobilizing tissue and for use in non-invasive methods of assessing lower urinary tract symptoms as well as in surgical application.

Abstract: Provided are devices and methods suitable for immobilizing tissue and for use in non-invasive methods of assessing lower urinary tract symptoms as well as in surgical application.

Abstract: Provided are devices and methods suitable for immobilizing tissue and for use in non-invasive methods of assessing lower urinary tract symptoms as well as in surgical application.

Abstract: Provided are devices and methods suitable for immobilizing tissue and for use in non-invasive methods of assessing lower urinary tract symptoms as well as in surgical application.

Abstract: Provided are devices and methods suitable for immobilizing tissue and for use in non-invasive methods of assessing lower urinary tract symptoms as well as in surgical application.

Abstract: Provided are devices and methods suitable for immobilizing tissue and for use in non-invasive methods of assessing lower urinary tract symptoms as well as in surgical application.